Based in Washington, D.C., Tony Jawhar delivers a host of healthcare solutions as Advanced Medical Systems CEO. A focus for Tony Jawhar is on assessing national and global healthcare trends, and he has a particular interest in spine surgery developments.
In May 2023, the FDA took a significant step in approving the use of Abbot spinal cord stimulation (SCS) devices for those who haven’t yet had back surgery. This decision followed a six-month study involving 200 patients who had on average more than a dozen years of chronic, disabling back pain. Reasons for not having back surgery included medical frailty and several degenerative spine issues that, while presenting significant symptoms, did not qualify for corrective surgery.
Over the course of the study, 85 percent of those who had the SCS device implanted registered a significant reduction in back pain. Effects spanned back function, pain, mental health, and quality of life improvements. This contrasted with improvements reported by only 7 percent of those who received conservative medical management.
Traditional spine stimulation systems employ “tonic stimulation,” which causes a tingling sensation in patients. In contrast, the latest generation SCS devices employ mild electrical energy that mimic electrical signals that the body normally sends. Rather than generating tingling, they mask pain-associated signals to the brain. The Abbot device is extremely small, around the size of a smartphone battery, and can be inserted in a minimally invasive procedure. Implantation typically requires one to two hours and can often be performed as an outpatient procedure.